W

Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871

Watchlist Manager
Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871
Watchlist
Price: 11.71 CNY -0.26% Market Closed
Market Cap: 1.9B CNY
Have any thoughts about
Wuhan Hvsen Biotechnology Co Ltd?
Write Note

Wuhan Hvsen Biotechnology Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Wuhan Hvsen Biotechnology Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
W
Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871
Pre-Tax Income
ÂĄ12.4m
CAGR 3-Years
-59%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Pre-Tax Income
ÂĄ3.8B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Pre-Tax Income
ÂĄ3.7B
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Pre-Tax Income
ÂĄ5.9B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Pre-Tax Income
ÂĄ5B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
5%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Pre-Tax Income
-ÂĄ769m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Wuhan Hvsen Biotechnology Co Ltd
Glance View

Market Cap
1.9B CNY
Industry
Pharmaceuticals

HVSEN Biotechnology Co., Ltd. engages in the research and development, production, and sale of veterinary drugs. The company is headquartered in Wuhan, Hubei and currently employs 828 full-time employees. The company went IPO on 2020-08-24. The Company’s main products include veterinary active pharmaceutical ingredients, veterinary chemical preparations, veterinary traditional Chinese medicine preparations, feed and additives and environmental improvers, such as tyvanicin tartrate, florfenicol powder, banqing granules and piglet composites pre-mixed feed, etc. The firm mainly conducts its businesses in the China market.

Intrinsic Value
22.35 CNY
Undervaluation 48%
Intrinsic Value
Price
W

See Also

What is Wuhan Hvsen Biotechnology Co Ltd's Pre-Tax Income?
Pre-Tax Income
12.4m CNY

Based on the financial report for Dec 31, 2023, Wuhan Hvsen Biotechnology Co Ltd's Pre-Tax Income amounts to 12.4m CNY.

What is Wuhan Hvsen Biotechnology Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-31%

Over the last year, the Pre-Tax Income growth was -78%. The average annual Pre-Tax Income growth rates for Wuhan Hvsen Biotechnology Co Ltd have been -59% over the past three years , -31% over the past five years .

Back to Top